Metabolic syndrome in patients with hematological diseases

References

• Conus F, Allison DB, Rabasa-Lhoret R et al. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J. Clin. Endocrinol. Metab. 89(10), 5013–5020 (2004).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14(3), 173–194 (1991).
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365(9468), 1415–1428 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34(6), 416–422 (1991).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109(3), 433–438 (2004).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41(6), 715–722 (1992).
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J. Am. Coll. Cardiol. 46(11), 1978–1985 (2005).
   PubMed Web of Science ®Google Scholar
• Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr. Diab. Rep. 4(1), 63–68 (2004).
   PubMedGoogle Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12), 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Richelsen B, Pedersen SB. Associations between different anthropometric measurements of fatness and metabolic risk parameters in non-obese, healthy, middle-aged men. Int. J. Obes. Relat. Metab. Disord. 19(3), 169–174 (1995).
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28(9), 2289–2304 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 366(9491), 1059–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Ordovas JM. Genetic links between diabetes mellitus and coronary atherosclerosis. Curr. Atheroscler. Rep. 9(3), 204–210 (2007).
   PubMedGoogle Scholar
• Matsuzawa Y. The role of fat topology in the risk of disease. Int. J. Obes. 32(Suppl. 7), S83–S92 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr. Pharm. Des. 16(17), 1896–1901 (2010).
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin. Sci. 110(3), 267–278 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone → cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 84(3), 1022–1027 (1999).
   PubMed Web of Science ®Google Scholar
• Valsamakis G, Anwar A, Tomlinson JW et al. 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89(9), 4755–4761 (2004).
   PubMed Web of Science ®Google Scholar
• Blendea MC, Jacobs D, Stump CS et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am. J. Physiol. Endocrinol. Metab. 288(2), e353–e359 (2005).
   PubMed Web of Science ®Google Scholar
• Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin–angiotensin–aldosterone system, glucose metabolism and diabetes. Trends Endocrinol. Metab. 16(3), 120–126 (2005).
   PubMed Web of Science ®Google Scholar
• Wei Y, Sowers JR, Nistala R et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J. Biol. Chem. 281(46), 35137–35146 (2006).
   PubMed Web of Science ®Google Scholar
• Brown NJ. Aldosterone and vascular inflammation. Hypertension 51(2), 161–167 (2008).
   PubMed Web of Science ®Google Scholar
• Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J. Hepatol. 50(6), 1226–1235 (2009).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 47(3), 312–318 (2006).
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31(9), 1898–1904 (2008).
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Magliano DJ, Zimmet PZ et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J. Intern. Med. 264(2), 177–186 (2008).
   PubMed Web of Science ®Google Scholar
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28(7), 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 119(10), 812–819 (2006).
   PubMed Web of Science ®Google Scholar
• Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49(4), 403–414 (2007).
   PubMed Web of Science ®Google Scholar
• Meigs JB, Wilson PW, Fox CS et al. Body mass index, metabolic syndrome, and risk of Type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 91(8), 2906–2912 (2006).
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and Type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch. Intern. Med. 167(7), 642–648 (2007).
   PubMedGoogle Scholar
• Ingelsson E, Sullivan LM, Murabito JM et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 56(6), 1718–1726 (2007).
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 143(10), 722–728 (2005).
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54(11), 3140–3147 (2005).
   PubMed Web of Science ®Google Scholar
• Marceau P, Biron S, Hould FS et al. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 84(5), 1513–1517 (1999).
   PubMed Web of Science ®Google Scholar
• Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern. Med. 140(3), 167–174 (2004).
   PubMed Web of Science ®Google Scholar
• Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 16(7), 2134–2140 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zuo L, Wang F et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin. Proc. 82(7), 822–827 (2007).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Anconetani B et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen–progestagen treatment. Clin. Endocrinol. 50(4), 517–527 (1999).
   PubMed Web of Science ®Google Scholar
• Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am. J. Respir. Crit. Care Med. 165(5), 670–676 (2002).
   PubMed Web of Science ®Google Scholar
• Vgontzas AN, Papanicolaou DA, Bixler EO et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab. 85(3), 1151–1158 (2000).
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 120(5), 442–447 (2007).
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 57(1), 109–115 (2007).
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab. 94(8), 2692–2701 (2009).
   PubMed Web of Science ®Google Scholar
• Collins L, Zarzabal LA, Nayiager T, Pollock BH, Barr RD. Growth in children with acute lymphoblastic leukemia during treatment. J. Pediatr. Hematol. Oncol. 32(8), e304–e307 (2010).
   PubMed Web of Science ®Google Scholar
• Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Mol. Biol. 122(1–3), 21–27 (2010).
   PubMed Web of Science ®Google Scholar
• Ge R, Huang Y, Liang G, Li X. 11β-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr. Med. Chem. 17(5), 412–422 (2010).
   PubMed Web of Science ®Google Scholar
• Hughes KA, Webster SP, Walker BR. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity. Expert Opin. Investig. Drugs 17(4), 481–496 (2008).
   PubMed Web of Science ®Google Scholar
• Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. J. Steroid Biochem. Mol. Biol. 85(2–5), 457–467 (2003).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Stewart PM. Mechanisms of disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat. Clin. Pract. Endocrinol. Metab. 1(2), 92–99 (2005).
   PubMedGoogle Scholar
• Wang M. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr. Opin. Investig. Drugs 7(4), 319–323 (2006).
   PubMedGoogle Scholar
• Peppa M, Koliaki C, Raptis SA. Adrenal incidentalomas and cardiometabolic morbidity: an emerging association with serious clinical implications. J. Intern. Med. 268(6), 555–566 (2010).
   PubMed Web of Science ®Google Scholar
• Comlekci A, Yener S, Ertilav S et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 37(1), 40–46 (2010).
   PubMed Web of Science ®Google Scholar
• Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28(11), 1357–1364 (2004).
   PubMed Web of Science ®Google Scholar
• Giacchetti G, Ronconi V, Turchi F et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25(1), 177–186 (2007).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 150(11), 776–783 (2009).
   PubMed Web of Science ®Google Scholar
• Rammos G, Tseke P, Ziakka S. Vitamin D, the renin–angiotensin system, and insulin resistance. Int. Urol. Nephrol. 40(2), 419–426 (2008).
   PubMed Web of Science ®Google Scholar
• Locsey L, Asztalos L, Kincses Z, Berczi C, Paragh G. The importance of obesity and hyperlipidaemia in patients with renal transplants. Int. Urol. Nephrol. 30(6), 767–775 (1998).
   PubMedGoogle Scholar
• Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl. Int. 18(4), 461–466 (2005).
   PubMed Web of Science ®Google Scholar
• Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl. 15(12), 1662–1670 (2009).
   PubMed Web of Science ®Google Scholar
• Keogh A. Calcineurin inhibitors in heart transplantation. J. Heart Lung Transplant. 23(Suppl. 5), S202–S206 (2004).
   Google Scholar
• Singh TP, Naftel DC, Webber S et al.; Pediatric Heart Transplant Study Group. Hyperlipidemia in children after heart transplantation. J. Heart Lung Transplant. 25(10), 1199–1205 (2006).
   PubMed Web of Science ®Google Scholar
• Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transplant. 23(Suppl. 5), S187–S193 (2004).
   Web of Science ®Google Scholar
• Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 14(11), 1648–1654 (2008).
   PubMed Web of Science ®Google Scholar
• Aguilar-Salinas CA, Díaz-Polanco A, Quintana E et al. Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am. J. Kidney Dis. 40(1), 169–177 (2002).
   PubMed Web of Science ®Google Scholar
• Baum CL, Thielke K, Westin E, Kogan E, Cicalese L, Benedetti E. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition 18(2), 139–146 (2002).
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 74(11), 1568–1573 (2002).
   PubMed Web of Science ®Google Scholar
• Siekierka-Harreis M, Kuhr N, Willers R et al. Impact of genetic polymorphisms of the renin–angiotensin system and of non-genetic factors on kidney transplant function – a single-center experience. Clin. Transplant. 23(5), 606–615 (2009).
   PubMed Web of Science ®Google Scholar
• Porrini E, Delgado P, Alvarez A et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol. Dial. Transplant. 23(4), 1436–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 89(9), 1134–1140 (2010).
   PubMed Web of Science ®Google Scholar
• Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J et al. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transplant. Proc. 40(9), 2994–2996 (2008).
   PubMed Web of Science ®Google Scholar
• Sessa A, Esposito A, Giliberti A et al. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients. Transplant. Proc. 41(4), 1178–1182 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman JR. Chronic calcineurin inhibitor nephrotoxicity – lest we forget. Am. J. Transplant. 11(4), 693–697 (2011).
   PubMed Web of Science ®Google Scholar
• Brown JH, Murphy BG, Douglas AF et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 75(3), 277–282 (1997).
   PubMed Web of Science ®Google Scholar
• Bohlke M, Barcellos FC, Rocha M, Gomes RH, Terhorst L, Marini SS. Predictors of hypertension following successful renal transplantation: a population-based study. Transplant. Proc. 41(9), 3743–3746 (2009).
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am. J. Clin. Nutr. 88(5), 1242–1247 (2008).
   PubMed Web of Science ®Google Scholar
• Lasocki A, Vote B, Fassett R, Zamir E. Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Ocul. Immunol. Inflamm. 15(4), 345–346 (2007).
   PubMed Web of Science ®Google Scholar
• Wagner N, Jehl-Piétri C, Lopez P et al. Peroxisome proliferator-activated receptor β stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc. Res. 83(1), 61–71 (2009).
   PubMed Web of Science ®Google Scholar
• Lo A. Immunosuppression and metabolic syndrome in renal transplant recipients. Metab. Syndr. Relat. Disord. 2(4), 263–273 (2004).
   PubMed Web of Science ®Google Scholar
• Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 64(18), 2047–2073 (2004).
   PubMed Web of Science ®Google Scholar
• Marchetti P. New-onset diabetes after transplantation. J. Heart Lung Transplant. 23(Suppl. 5), S194–S201 (2004).
   Google Scholar
• Sui W, Zou H, Zou G et al. Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. Transpl. Immunol. 20(1–2), 95–98 (2008).
   PubMed Web of Science ®Google Scholar
• Ersoy A, Baran B, Ersoy C, Kahvecioglu S, Akdag I. Calcineurin inhibitors and post-transplant weight gain. Nephrology 13(5), 433–439 (2008).
   PubMed Web of Science ®Google Scholar
• Niehof M, Borlak J. HNF4α dysfunction as a molecular rational for cyclosporine induced hypertension. PLoS ONE 6(1), e16319 (2011).
   Google Scholar
• Bai JP, Lesko LJ, Burckart GJ. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 30(2), 195–209 (2010).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xie XB, Peng LK et al. Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes. Transplant. Proc. 43(5), 1612–1615 (2011).
   PubMed Web of Science ®Google Scholar
• Kalantar E, Khalili N, Hossieni MS, Rostami Z, Einollahi B. Hyperuricemia after renal transplantation. Transplant. Proc. 43(2), 584–585 (2011).
   PubMed Web of Science ®Google Scholar
• Law YM, Yim R, Agatisa P et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J. Heart Lung Transplant. 25(3), 276–282 (2006).
   PubMed Web of Science ®Google Scholar
• Nash EF, Stephenson A, Helm EJ et al. Impact of lung transplantation on serum lipids in adults with cystic fibrosis. J. Heart Lung Transplant. 30(2), 188–193 (2011).
   PubMed Web of Science ®Google Scholar
• Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int. Urol. Nephrol. 40(2), 521–527 (2008).
   PubMed Web of Science ®Google Scholar
• Seibert F, Behrendt C, Schmidt S, van der Giet M, Zidek W, Westhoff TH. Differential effects of cyclosporine and tacrolimus on arterial function. Transpl. Int. 24(7), 708–715 (2011).
   PubMed Web of Science ®Google Scholar
• Seymen P, Yildiz M, Türkmen MF, Titiz MI, Seymen HO. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. Transplant. Proc. 41(10), 4181–4183 (2009).
   PubMed Web of Science ®Google Scholar
• Zawiasa A, Szklarek-Kubicka M, Fijalkowska-Morawska J et al. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. Transplant. Proc. 41(1), 188–191 (2009).
   PubMed Web of Science ®Google Scholar
• Deleuze S, Garrigue V, Delmas S et al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? Transplant. Proc. 38(7), 2311–2313 (2006).
   PubMed Web of Science ®Google Scholar
• Marcén R, Fernández A, Pascual J et al. High body mass index and posttransplant weight gain are not risk factors for kidney graft and patient outcome. Transplant. Proc. 39(7), 2205–2207 (2007).
   PubMed Web of Science ®Google Scholar
• el-Agroudy AE, Wafa EW, Gheith OE, Shehab el-Dein AB, Ghoneim MA. Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation 77(9), 1381–1385 (2004).
   PubMed Web of Science ®Google Scholar
• Ablassmaier B, Klaua S, Jacobi CA, Müller JM. Laparoscopic gastric banding after heart transplantation. Obes. Surg. 12(3), 412–415 (2002).
   PubMed Web of Science ®Google Scholar
• Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin. Transplant. 10(5), 414–419 (1996).
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang ZR, Chou CF, Liang YY, Gu Y, Ma HP. Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol. Am. J. Physiol. Renal Physiol. 296(2), F284–F290 (2009).
   Web of Science ®Google Scholar
• Damiano S, Scanni R, Ciarcia R, Florio S, Capasso G. Regulation of sodium transporters in the kidney during cyclosporine treatment. J. Nephrol. 23(Suppl. 16), S191–S198 (2010).
   Google Scholar
• Mathew R, Huang J, Katta US, Krishnan U, Sandoval C, Gewitz MH. Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension. J. Pediatr. Hematol. Oncol. 33(1), 55–58 (2011).
   PubMed Web of Science ®Google Scholar
• Mangray M, Vella JP. Hypertension after kidney transplant. Am. J. Kidney Dis. 57(2), 331–341 (2011).
   PubMed Web of Science ®Google Scholar
• Illsinger S, Janzen N, Lücke T et al. Cyclosporine A: impact on mitochondrial function in endothelial cells. Clin. Transplant. 25(4), 584–593 (2011).
   PubMed Web of Science ®Google Scholar
• Melnikov S, Mayan H, Uchida S, Holtzman EJ, Farfel Z. Cyclosporine metabolic side effects: association with the WNK4 system. Eur. J. Clin. Invest. 41(10), 1113–1120 (2011).
   PubMed Web of Science ®Google Scholar
• Bandukwala F, Huang M, Prasad GV. Role of uric acid in post-renal transplantation hypertension. Transplant. Proc. 41(5), 1634–1636 (2009).
   PubMed Web of Science ®Google Scholar
• Menè P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J. Hypertens. 26(11), 2085–2092 (2008).
   PubMed Web of Science ®Google Scholar
• White M, Haddad H, Leblanc MH et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J. Heart Lung Transplant. 24(7), 798–809 (2005).
   PubMed Web of Science ®Google Scholar
• Rodrigo E, Ruiz JC, Angeles de Cos M et al. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transplant. Proc. 41(6), 2328–2331 (2009).
   PubMed Web of Science ®Google Scholar
• Sánchez Pérez B, Aranda Narváez JM, Suárez Muñoz MA et al. Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels. Transplant. Proc. 41(3), 1028–1029 (2009).
   PubMed Web of Science ®Google Scholar
• Kockx M, Guo DL, Traini M et al. Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway. J. Biol. Chem. 284(36), 24144–24154 (2009).
   PubMed Web of Science ®Google Scholar
• Tory R, Sachs-Barrable K, Hill JS, Wasan KM. Cyclosporine A and rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. Int. J. Pharm. 358(1–2), 219–223 (2008).
   PubMedGoogle Scholar
• Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant. 36(8), 739–740 (2005).
   PubMed Web of Science ®Google Scholar
• Gumprecht J, Zychma M, Grzeszczak W et al. Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient. Med. Sci. Monit. 9(9), CS89–CS91 (2003).
   PubMedGoogle Scholar
• Launay-Vacher V, Izzedine H, Deray G. Statins’ dosage in patients with renal failure and cyclosporine drug–drug interactions in transplant recipient patients. Int. J. Cardiol. 101(1), 9–17 (2005).
   PubMed Web of Science ®Google Scholar
• Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J. Cancer Surviv. 1(4), 261–274 (2007).
   PubMedGoogle Scholar
• Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J. Natl. Compr. Canc. Netw. 4(10), 1059–1070 (2006).
   PubMedGoogle Scholar
• Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin. Adv. Hematol. Oncol. 4(9), 687–696 (2006).
   PubMedGoogle Scholar
• Redig AJ, Munshi HG. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology 24(9), 839–844 (2010).
   PubMed Web of Science ®Google Scholar
• Oh SW, Park CY, Lee ES et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res. 13(2), R34 (2011).
   Google Scholar
• Stebbing J, Sharma A, North B et al. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann. Oncol. 23(4), 860–866 (2012).
   PubMed Web of Science ®Google Scholar
• Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G. Adiposity in childhood cancer survivors: insights into obesity physiopathology. Arq. Bras. Endocrinol. Metabol. 53(2), 190–200 (2009).
   PubMedGoogle Scholar
• Thomson CA, Thompson PA, Wright-Bea J, Nardi E, Frey GR, Stopeck A. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J. Womens Health (Larchmt). 18(12), 2041–2047 (2009).
   PubMed Web of Science ®Google Scholar
• Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev. Mol. Diagn. 10(4), 509–519 (2010).
   PubMed Web of Science ®Google Scholar
• Beaulieu LM, Whitley BR, Wiesner TF et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays 29(10), 1029–1038 (2007).
   PubMed Web of Science ®Google Scholar
• Capasso I, Esposito E, Pentimalli F et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol. Ther. 10(12), 1240–1243 (2011).
   Web of Science ®Google Scholar
• Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat. Rev. Urol. 8(9), 483–494 (2011).
   PubMed Web of Science ®Google Scholar
• Casas F, Borràs JM, Ferrer F et al. Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. Clin. Transl. Oncol. 12(5), 346–355 (2010).
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Aass N, Fosså SD et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann. Oncol. 18(2), 241–248 (2007).
   PubMed Web of Science ®Google Scholar
• Wethal T, Kjekshus J, Røislien J et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J. Cancer Surviv. 1(1), 8–16 (2007).
   PubMedGoogle Scholar
• Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J. Clin. Oncol. 23(16), 3718–3725 (2005).
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur. J. Cancer 40(5), 701–706 (2004).
   PubMed Web of Science ®Google Scholar
• Oliver T. Conservative management of testicular germ-cell tumors. Nat. Clin. Pract. Urol. 4(10), 550–560 (2007).
   PubMedGoogle Scholar
• Bain J. The many faces of testosterone. Clin. Interv. Aging 2(4), 567–576 (2007).
   PubMed Web of Science ®Google Scholar
• Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J. Androl. 30(1), 10–22 (2009).
   PubMed Web of Science ®Google Scholar
• Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J. Androl. 30(1), 23–32 (2009).
   PubMedGoogle Scholar
• Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat. Rev. Endocrinol. 5(12), 673–681 (2009).
   PubMed Web of Science ®Google Scholar
• Gravholt CH, Jensen AS, Høst C, Bojesen A. Body composition, metabolic syndrome and Type 2 diabetes in Klinefelter syndrome. Acta Paediatr. 100(6), 871–877 (2011).
   PubMed Web of Science ®Google Scholar
• Sode-Carlsen R, Farholt S, Rabben KF et al. Body composition, endocrine and metabolic profiles in adults with Prader–Willi syndrome. Growth Horm. IGF Res. 20(3), 179–184 (2010).
   PubMed Web of Science ®Google Scholar
• El-Mansoury M, Barrenäs ML, Bryman I, Hanson C, Landin-Wilhelmsen K. Impaired body balance, fine motor function and hearing in women with Turner syndrome. Clin. Endocrinol. 71(2), 273–278 (2009).
   PubMed Web of Science ®Google Scholar
• Koulouri O, Ostberg J, Conway GS. Liver dysfunction in Turner’s syndrome: prevalence, natural history and effect of exogenous oestrogen. Clin. Endocrinol. 69(2), 306–310 (2008).
   PubMed Web of Science ®Google Scholar
• Mancini A, Zollino M, Leone E et al. A case of 45,X male: genetic reevaluation and hormonal and metabolic follow-up in adult age. Fertil. Steril. 90(5), 2011.e17–2011.e21 (2008).
   Google Scholar
• Grossmann M. Low testosterone in men with Type 2 diabetes: significance and treatment. J. Clin. Endocrinol. Metab. 96(8), 2341–2353 (2011).
   PubMed Web of Science ®Google Scholar
• Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am. J. Med. 124(7), 578–587 (2011).
   PubMed Web of Science ®Google Scholar
• Miner MM, Khera M, Bhattacharya RK, Blick G, Kushner H. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad. Med. 123(3), 17–27 (2011).
   PubMed Web of Science ®Google Scholar
• Katabami T, Kato H, Asahina T et al. Serum free testosterone and metabolic syndrome in Japanese men. Endocr. J. 57(6), 533–539 (2010).
   PubMed Web of Science ®Google Scholar
• Mah PM, Wittert GA. Obesity and testicular function. Mol. Cell. Endocrinol. 316(2), 180–186 (2010).
   PubMed Web of Science ®Google Scholar
• Tsujimura A, Takada S, Matsuoka Y et al. Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: is there a link? Int. J. Urol. 16(10), 830–835 (2009).
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM et al.; TIMES2 Investigators. Testosterone replacement in hypogonadal men with Type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34(4), 828–837 (2011).
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin. Endocrinol. 73(5), 602–612 (2010).
   PubMed Web of Science ®Google Scholar
• Ozhan H, Aydin M, Yazici M et al. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets 21(1), 29–32 (2010).
   PubMed Web of Science ®Google Scholar
• Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int. J. Clin. Pract. 63(10), 1509–1515 (2009).
   PubMed Web of Science ®Google Scholar
• Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets 23(1), 45–50 (2012).
   PubMed Web of Science ®Google Scholar
• Vaidya D, Yanek LR, Faraday N, Moy TF, Becker LC, Becker DM. Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. Metab. Syndr. Relat. Disord. 7(4), 289–296 (2009).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J. Thromb. Thrombolysis 25(2), 207–213 (2008).
   PubMed Web of Science ®Google Scholar
• Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. NY Acad. Sci. 1212, e1–e19 (2010).
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J. Thromb. Haemost. 5(8), 1637–1643 (2007).
   PubMed Web of Science ®Google Scholar
• Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83(3), 847–850 (1998).
   PubMed Web of Science ®Google Scholar
• Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 34(1), 2–11 (2008).
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern. Emerg. Med. 7(1), 9–13 (2012).
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Tufano A, Guida A et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb. Res. 127(3), 193–197 (2011).
   PubMed Web of Science ®Google Scholar
• Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J. Thromb. Haemost. 5(Suppl. 1), 270–275 (2007).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol. Metab. Clin. North Am. 33(2), 431–53 (2004).
   PubMed Web of Science ®Google Scholar
• Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med. Wkly 132(19–20), 241–252 (2002).
   PubMed Web of Science ®Google Scholar
• Palomo I, Alarcón M, Moore-Carrasco R, Argilés JM. Hemostasis alterations in metabolic syndrome (review). Int. J. Mol. Med. 18(5), 969–974 (2006).
   PubMed Web of Science ®Google Scholar
• Kotronen A, Joutsi-Korhonen L, Sevastianova K et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 31(2), 176–183 (2011).
   PubMed Web of Science ®Google Scholar
• Lim HS, Lip GY, Blann AD. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J. Clin. Endocrinol. Metab. 89(11), 5377–5381 (2004).
   PubMed Web of Science ®Google Scholar
• Ragab A, Abousamra NK, Higazy A, Saleh O. Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome. Lab. Hematol. 14(1), 1–6 (2008).
   PubMedGoogle Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P et al. Survival and complications in thalassemia. Ann. NY Acad. Sci. 1054, 40–47 (2005).
   PubMed Web of Science ®Google Scholar
• Cavallo-Perin P, Pacini G, Cerutti F et al. Insulin resistance and hyperinsulinemia in homozygous β-thalassemia. Metab. Clin. Exp. 44(3), 281–286 (1995).
   PubMed Web of Science ®Google Scholar
• Delvecchio M, Cavallo L. Growth and endocrine function in thalassemia major in childhood and adolescence. J. Endocrinol. Invest. 33(1), 61–68 (2010).
   PubMed Web of Science ®Google Scholar
• Zachmann M, Kempken B, De Sanctis V. Acute metabolic effects of human growth hormone on 15N-nitrogen balance in patients with thalassaemia as compared to patients with other types of short stature. J. Pediatr. Endocrinol. Metab. 11(Suppl. 3), 851–856 (1998).
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355(9220), 2051–2052 (2000).
   PubMed Web of Science ®Google Scholar
• Merkel PA, Simonson DC, Amiel SA et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N. Engl. J. Med. 318(13), 809–814 (1988).
   PubMed Web of Science ®Google Scholar
• Jones TW, Boulware SD, Caprio S et al. Correction of hyperinsulinemia by glyburide treatment in nondiabetic patients with thalassemia major. Pediatr. Res. 33(5), 497–500 (1993).
   PubMed Web of Science ®Google Scholar
• Mangiagli A, Campisi S, De Sanctis V et al.; Study Group of the Italian Pediatric and Diabetes Soceity (SIEDP) on Endocrine Complicaionts in Non-Endocrine Disease. Effects of acarbose in β-thalassaemia major patients with normal glucose tolerance and hyperinsulinism. Pediatr. Endocrinol. Rev. 2(Suppl. 2), 272–275 (2004).
   PubMedGoogle Scholar
• Caprio S, Amiel SA, Merkel P, Tamborlane WV. Insulin-resistant syndromes in children. Horm. Res. 39(Suppl. 3), 112–114 (1993).
   PubMedGoogle Scholar
• Pappas S, Donohue SM, Denver AE, Mohamed-Ali V, Goubet S, Yudkin JS. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metab. Clin. Exp. 45(5), 652–657 (1996).
   PubMed Web of Science ®Google Scholar
• Hafez M, Youssry I, El-Hamed FA, Ibrahim A. Abnormal glucose tolerance in β-thalassemia: assessment of risk factors. Hemoglobin 33(2), 101–108 (2009).
   PubMed Web of Science ®Google Scholar
• Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. Abnormal glucose tolerance in Egyptian β-thalassemic patients: possible association with genotyping. Pediatr. Diabetes 5(3), 126–132 (2004).
   PubMed Web of Science ®Google Scholar
• Sougleri M, Labropoulou-Karatza C, Paraskevopoulou P, Fragopanagou H, Alexandrides T. Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with α-thalassaemia major. Eur. J. Gastroenterol. Hepatol. 13(10), 1195–1199 (2001).
   PubMed Web of Science ®Google Scholar
• Tong PC, Ng MC, Ho CS et al. C-reactive protein and insulin resistance in subjects with thalassemia minor and a family history of diabetes. Diabetes Care 25(8), 1480–1481 (2002).
   PubMed Web of Science ®Google Scholar
• Tsapas A, Vlachaki E, Christoforidis A et al. Insulin sensitivity assessment with euglycemic insulin clamp in adult β-thalassaemia major patients. Eur. J. Haematol. 79(6), 526–530 (2007).
   PubMed Web of Science ®Google Scholar
• Christoforidis A, Perifanis V, Tsatra I, Vlachaki E, Athanassiou-Metaxa M. Evolution of OGTT in patients with β-thalassaemia major in relation to chelation therapy. Diabetes Res. Clin. Pract. 76(1), 6–11 (2007).
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Chareonmuang R, Wongcharnchailert M, Laosombat V, Sangsupavanich P, Leetanaporn K. Prevalence of impaired glucose metabolism in β-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur. J. Pediatr. 167(8), 873–876 (2008).
   PubMed Web of Science ®Google Scholar
• Dwivedi S, Kumar V. β-thalassemia, hyperlipoproteinemia(a), and metabolic syndrome: its low-cost holistic therapy. J. Altern. Complement. Med. 13(2), 287–289 (2007).
   PubMed Web of Science ®Google Scholar
• Oeffinger KC. Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr. Blood Cancer 50(Suppl. 2), 462–467; discussion 468 (2008).
   PubMed Web of Science ®Google Scholar
• Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G. Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc. Health Risk Manag. 4(4), 825–836 (2008).
   PubMedGoogle Scholar
• van Waas M, Neggers SJ, van der Lelij AJ, Pieters R, van den Heuvel-Eibrink MM. The metabolic syndrome in adult survivors of childhood cancer, a review. J. Pediatr. Hematol. Oncol. 32(3), 171–179 (2010).
   PubMed Web of Science ®Google Scholar
• Childhood Acute Lymphoblastic Leukaemia Collaborative Group. Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br. J. Haematol. 145(3), 376–388 (2009).
   PubMed Web of Science ®Google Scholar
• Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 115(1), 23–35 (2009).
   PubMed Web of Science ®Google Scholar
• Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 356(9234), 993–997 (2000).
   PubMed Web of Science ®Google Scholar
• Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur. J. Endocrinol. 153(1), 81–89 (2005).
   PubMed Web of Science ®Google Scholar
• Socié G. Is syndrome ‘X’ another late complication of bone-marrow transplantation?. Lancet 356(9234), 957–958 (2000).
   PubMed Web of Science ®Google Scholar
• Follin C, Thilén U, Osterberg K, Björk J, Erfurth EM. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J. Clin. Endocrinol. Metab. 95(8), 3726–3735 (2010).
   PubMed Web of Science ®Google Scholar
• Kourti M, Tragiannidis A, Makedou A, Papageorgiou T, Rousso I, Athanassiadou F. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J. Pediatr. Hematol. Oncol. 27(9), 499–501 (2005).
   PubMed Web of Science ®Google Scholar
• Gurney JG, Ness KK, Sibley SD et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 107(6), 1303–1312 (2006).
   PubMed Web of Science ®Google Scholar
• Oudin C, Simeoni MC, Sirvent N et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 117(17), 4442–4448 (2011).
   PubMed Web of Science ®Google Scholar
• Surapolchai P, Hongeng S, Mahachoklertwattana P et al. Impaired glucose tolerance and insulin resistance in survivors of childhood acute lymphoblastic leukemia: prevalence and risk factors. J. Pediatr. Hematol. Oncol. 32(5), 383–389 (2010).
   PubMed Web of Science ®Google Scholar
• Steinberger J, Sinaiko AR, Kelly AS et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. J. Pediatr. 160(3), 494–499 (2012).
   PubMed Web of Science ®Google Scholar
• Trimis G, Moschovi M, Papassotiriou I, Chrousos G, Tzortzatou-Stathopoulou F. Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease. J. Pediatr. Hematol. Oncol. 29(5), 309–314 (2007).
   PubMed Web of Science ®Google Scholar
• Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 16(4), 225–243 (2002).
   PubMed Web of Science ®Google Scholar
• Gregory JW. Metabolic disorders. Endocr. Dev. 15, 59–76 (2009).
   PubMedGoogle Scholar
• van Waas M, Neggers SJ, Te Winkel ML, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM. Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. Ann. Oncol. 23(6), 1626–1632 (2012).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Bregni M, Brune M et al.; European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 45(2), 219–234 (2010).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M et al.; European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 37(5), 439–449 (2006).
   PubMed Web of Science ®Google Scholar
• Goldman JM, Majhail NS, Klein JP et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin. Oncol. 28(11), 1888–1895 (2010).
   PubMed Web of Science ®Google Scholar
• Abou-Mourad YR, Lau BC, Barnett MJ et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 45(2), 295–302 (2010).
   PubMed Web of Science ®Google Scholar
• Majhail NS, Flowers ME, Ness KK et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 43(1), 49–54 (2009).
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100(5), 1602–1610 (2002).
   PubMed Web of Science ®Google Scholar
• Vonk MC, Marjanovic Z, van den Hoogen FH et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann. Rheum. Dis. 67(1), 98–104 (2008).
   PubMed Web of Science ®Google Scholar
• Baker KS, Bresters D, Sande JE. The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children. Pediatr. Clin. North Am. 57(1), 323–342 (2010).
   PubMed Web of Science ®Google Scholar
• Demarosi F, Lodi G, Carrassi A, Soligo D, Sardella A. Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol. 41(9), 865–877 (2005).
   PubMed Web of Science ®Google Scholar
• Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 13(10), 1121–1134 (2007).
   PubMed Web of Science ®Google Scholar
• Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin. Oncol. 35(4), 418–429 (2008).
   PubMed Web of Science ®Google Scholar
• Lambertenghi Deliliers G, Annaloro C, Pozzoli E et al. Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation. Leuk. Res. 23(3), 291–297 (1999).
   PubMed Web of Science ®Google Scholar
• Hertenstein B, Hambach L, Bacigalupo A et al.; Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Development of leukemia in donor cells after allogeneic stem cell transplantation – a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 90(7), 969–975 (2005).
   PubMed Web of Science ®Google Scholar
• Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br. J. Haematol. 118(1), 58–66 (2002).
   PubMed Web of Science ®Google Scholar
• Fazelzadeh A, Mehdizadeh A, Ostovan MA, Raiss-Jalali GA. Incidence of cardiovascular risk factors and complications before and after kidney transplantation. Transplant. Proc. 38(2), 506–508 (2006).
   PubMed Web of Science ®Google Scholar
• Jericó C, Knobel H, Montero M et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28(1), 132–137 (2005).
   PubMed Web of Science ®Google Scholar
• Muñoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl. (11 Suppl. 2), S52–S56 (2005).
   Google Scholar
• Tsai PH, Sahdev I, Herry A, Lipton JM. Fatal cyclophosphamide-induced congestive heart failure in a 10-year-old boy with Shwachman–Diamond syndrome and severe bone marrow failure treated with allogeneic bone marrow transplantation. Am. J. Pediatr. Hematol. Oncol. 12(4), 472–476 (1990).
   PubMedGoogle Scholar
• Faraci M, Békássy AN, De Fazio V, Tichelli A, Dini G; EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant. 41(Suppl. 2), S49–S57 (2008).
   Google Scholar
• Lin YC, Liang TH, Chang HN, Lin JS, Lin HY. Behçet disease associated with myelodysplastic syndrome. J. Clin. Rheumatol. 14(3), 169–174 (2008).
   PubMed Web of Science ®Google Scholar
• Sánchez NB, Canedo IF, García-Patos PE, de Unamuno Pérez P, Benito AV, Pascual AM. Paraneoplastic vasculitis associated with multiple myeloma. J. Eur. Acad. Dermatol. Venereol. 18(6), 731–735 (2004).
   PubMed Web of Science ®Google Scholar
• Ferreira S, D’Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology 44(4), 434–442 (2005).
   PubMed Web of Science ®Google Scholar
• Fleming JN, Nash RA, McLeod DO et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3(1), e1452 (2008).
   PubMed Web of Science ®Google Scholar
• Massarotti EM, Schur PH. To what extent can preventive treatments prevent damage from systemic lupus erythematosus? Curr. Rheumatol. Rep. 13(4), 317–323 (2011).
   PubMed Web of Science ®Google Scholar
• Miller DV, Maleszewski JJ. The pathology of large-vessel vasculitides. Clin. Exp. Rheumatol. 29(1 Suppl. 64), S92–S98 (2011).
   PubMed Web of Science ®Google Scholar
• Miniati I, Guiducci S, Conforti ML et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann. Rheum. Dis. 68(1), 94–98 (2009).
   PubMed Web of Science ®Google Scholar
• Reny JL, Paul JF, Lefèbvre C et al. Association of Takayasu’s arteritis and Crohn’s disease. Results of a study on 44 Takayasu patients and review of the literature. Ann. Med. Interne (Paris). 154(2), 85–90 (2003).
   PubMedGoogle Scholar
• Shulman HM, Hinterberger W. Hepatic veno-occlusive disease–liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 10(3), 197–214 (1992).
   PubMed Web of Science ®Google Scholar
• Tishkin SM, Rekalov VV, Ivanova IV, MoreLand RS, Soloviev AI. Ionizing non-fatal whole-body irradiation inhibits Ca2+-dependent K+ channels in endothelial cells of rat coronary artery: possible contribution to depression of endothelium-dependent vascular relaxation. Int. J. Radiat. Biol. 83(3), 161–169 (2007).
   PubMed Web of Science ®Google Scholar
• Auner HW, Tinchon C, Brezinschek RI et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur. J. Haematol. 69(1), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• Gardner SF, Lazarus HM, Bednarczyk EM et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant. 12(2), 139–144 (1993).
   PubMed Web of Science ®Google Scholar
• Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant. 35(4), 323–334 (2005).
   PubMed Web of Science ®Google Scholar
• Mori T, Yanagi N, Maruyama T et al. Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. Jpn. Heart J. 43(3), 249–261 (2002).
   PubMedGoogle Scholar
• Mouthon MA, Vereycken-Holler V, Van der Meeren A, Gaugler MH. Irradiation increases the interactions of platelets with the endothelium in vivo: analysis by intravital microscopy. Radiat. Res. 160(5), 593–599 (2003).
   PubMed Web of Science ®Google Scholar
• Takatsuka H, Wakae T, Mori A, Okada M, Okamoto T, Kakishita E. Effects of total body irradiation on the vascular endothelium. Clin. Transplant. 16(5), 374–377 (2002).
   PubMed Web of Science ®Google Scholar
• Chen W, Chatta GS, Rubin WD et al. T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis. J. Immunol. 161(2), 909–918 (1998).
   PubMed Web of Science ®Google Scholar
• Collins MP, Periquet MI. Vasculitic neuropathy in chronic graft-versus-host disease (GVHD). J. Neurol. Sci. 175(1), 71–73 (2000).
   PubMed Web of Science ®Google Scholar
• Grigg A, Buchanan M, Whitford H. Late-onset pulmonary arterial hypertension in association with graft-versus-host disease after allogeneic stem-cell transplantation. Am. J. Hematol. 80(1), 38–42 (2005).
   PubMed Web of Science ®Google Scholar
• Ma M, Barnes G, Pulliam J, Jezek D, Baumann RJ, Berger JR. CNS angiitis in graft vs host disease. Neurology 59(12), 1994–1997 (2002).
   PubMed Web of Science ®Google Scholar
• Sostak P, Padovan CS, Eigenbrod S et al. Cerebral angiitis in four patients with chronic GVHD. Bone Marrow Transplant. 45(7), 1181–1188 (2010).
   PubMed Web of Science ®Google Scholar
• Conrad R, Remberger M, Cederlund K, Barkholt L. Cytokine expression in tumors treated with donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. Immunotherapy 3(3), 443–451 (2011).
   PubMed Web of Science ®Google Scholar
• Goussetis E, Varela I, Peristeri I et al. Cytokine gene polymorphisms and graft-versus-host disease in children after matched sibling hematopoietic stem cell transplantation: a single-center experience. Cell. Mol. Immunol. 8(3), 276–280 (2011).
   PubMed Web of Science ®Google Scholar
• Poloni A, Sartini D, Emanuelli M et al. Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. Cytokine 53(3), 376–383 (2011).
   PubMed Web of Science ®Google Scholar
• Nakasone H, Binh PN, Yamazaki R et al. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. Blood 117(12), 3469–3472 (2011).
   PubMed Web of Science ®Google Scholar
• Tauchmanovà L, Matarese G, Carella C et al. High serum leptin in patients with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Transplantation 78(9), 1376–1383 (2004).
   PubMed Web of Science ®Google Scholar
• Karthaus M, Gabrysiak T, Brabant G et al. Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplant. 20(8), 697–699 (1997).
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Shigematsu H, Gondo H, Okamura T, Niho Y. Autoreactive antibodies following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 22(7), 729–731 (1998).
   PubMed Web of Science ®Google Scholar
• Lambertenghi-Deliliers GL, Annaloro C, Della Volpe A, Oriani A, Pozzoli E, Soligo D. Multiple autoimmune events after autologous bone marrow transplantation. Bone Marrow Transplant. 19(7), 745–747 (1997).
   PubMed Web of Science ®Google Scholar
• Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun. Rev. 7(3), 198–203 (2008).
   PubMed Web of Science ®Google Scholar
• Shalitin S, Phillip M, Stein J, Goshen Y, Carmi D, Yaniv I. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 37(12), 1109–1117 (2006).
   PubMed Web of Science ®Google Scholar
• Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 15(9), 1100–1107 (2009).
   PubMed Web of Science ®Google Scholar
• Meacham LR, Sklar CA, Li S et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch. Intern. Med. 169(15), 1381–1388 (2009).
   PubMed Web of Science ®Google Scholar
• Chatterjee R, Palla K, McGarrigle HH, Mackinnon S, Mckinnon S, Kottaridis PD. Syndrome ‘X’ in adult female recipients of bone marrow transplantation for haematological malignancies. Bone Marrow Transplant. 35(2), 209–210 (2005).
   PubMed Web of Science ®Google Scholar
• Annaloro C, Usardi P, Airaghi L et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 41(9), 797–804 (2008).
   PubMed Web of Science ®Google Scholar
• Tichelli A, Bhatia S, Socié G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br. J. Haematol. 142(1), 11–26 (2008).
   PubMed Web of Science ®Google Scholar
• Tichelli A, Passweg J, Wójcik D et al.; EBMT Late Effects Working Party. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 93(8), 1203–1210 (2008).
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat. Rev. 28(4), 195–214 (2002).
   PubMed Web of Science ®Google Scholar
• Miccoli R, Bianchi C, Odoguardi L et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr. Metab. Cardiovasc. Dis. 15(4), 250–254 (2005).
   PubMed Web of Science ®Google Scholar
• Airaghi L, Usardi P, Forti S et al. A comparison between metabolic syndrome post-hematopoietic stem cell transplantation and spontaneously occurring metabolic syndrome. J. Endocrinol. Invest. 34(1), e6–e11 (2011).
   Google Scholar
• Baker KS, Ness KK, Steinberger J et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 109(4), 1765–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Tichelli A, Bucher C, Rovó A et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 110(9), 3463–3471 (2007).
   PubMed Web of Science ®Google Scholar